

## PE VC TO SOLETON

## RECEIPT FROM PTO FOR INDICATED ITEMS

(Do <u>NOT</u> Use for New or Continuing Applications of <u>Any</u> Kind)
Use 2 postcards for all New Applns. (cont/Div/CIP, too)
Use this sheet when filing CPA




` <u>`</u>		Atty: Thomas A. Cawley, Jr./JB:K.S. Hines						
ENT& THE OPIN. No: 09/1	772,938	Atty: Thomas A. Cawley, 01,702,140						
First Inventor:	In. No: 09/772,938 Date: June 9, 2003 Inventor: Nabil HANNA <i>et al.</i> Matter No: 276658							
T ii St iii Void		Client No: 37003						
		Client No. 37333						
	Response/Amendment 🔲 Appo	<b>2000</b>						
_	Completion Request for R 53(f)/PC							
.,	No. of Pages Abstract							
	No. of Pages Spec and Claims							
••	No. of Numbered Claims Only	)						
#	No. of Sheets of Drawings (Figs	st Informal Cover Letter						
		t mome						
	Declaration	of pages						
	Assignment	Cover Sheet						
	Small Entity Declaration							
	Extension Petition (PAT-111)							
#	# No. of Priority Documents							
	☐ IDS Letter ☐ Cited Appln(s) ☐ Foreign Sch Rep/OA							
	☐ PTO-1449 ☐ Cited Documents							
	☐ Issue Fee Transmittal Form PTOL-85(b) in duplicate							
\$	Amount Requested be	Charged to our Dep. Acct. No. 03-3975						
OTHER:								
	Current DUE DATE:	July 8, 2003						

(Submit Single Copy Only)

## TES PATENT AND TRADEMARK OFFICE

PATENT APPLICATION



Group Art Unit

Nabil HANNA et al.

Appln. No.: Series Code ↑

January 31, 2001 Filed: Mail Stop Non-Fee Amendment Hon. Commissioner for Patents

PO Box 1450

Inventor(s):

Alexandria, VA 22313-1450

Sir:

1644

Phillip Gambel Examiner: 1999-30-0466CP2 276658 Atty. Dkt. Client Ref

TREATMENT OF B CELL Appln. Title:

MALIGNANCIES USING COMBINATION OF B CELL

DEPLETING ANTIBODY AND IMMUNE MODULATING ANTIBODY RELATED

**APPLICATIONS** 

June 9, 2003 Date:

REPLY/AMENDMENT/LETTER This is a reply/amendment/letter in the above-identified application and includes the herewith attachment of same date and subject which is incorporated hereinto by reference and the signature below is treated as the signature to the attachment in absence of a

FEE REQUIREMENTS FOR CLAIMS AS AMENDED signature thereto.

signature triefeto.	FEE REQUIR	KEWEN12 FO	JK CL	AIMS AS AMEND	<del></del>			
1. Small Entity claim  A. ⊠ NOT made  B. ☐ Withdrawn  C. ☐ made herewith  D. ☐ made previously  A. See Required Separate Paper (Pat-256)	Claims remaining after amendment	Highest num previously pa	nber aid for	Present Extra	Large/Small Entity	Additional Fee	Fee Code Lg/Sm	
			T 04		x \$18/\$9 =	+ \$0	103/203	
2. Total Effective Claims	21	**minus	21	0	x \$84/\$42 =	+ \$0	102/202	
3. Independent Claims	le dependent o	***minus claim(s) into	3 this ap	plication for first	+ \$280/\$140 =	+ \$0	104/204	
time (leave blank if this is a reissue a	pplication,			- A CONTRACTOR OF THE SECOND	-1. 3 L. 4563	E Carlo Landina		
5. Original due Date: July 8, 2003  6. Petition is hereby made to extend the original due date to cover the date this response is filed for which the requisite fee is attached  (1 mo) \$110/\$55 = \$410/\$205 = \$410/\$205 = \$930/\$465 = \$930/\$465 = \$1,450/\$725 = \$1,970/\$985 = \$1,970/\$985 =							115/215 116/216 117/217 118/218 128/228	
7. Enter any previous extension fee <u>paid</u> since above <u>original</u> due date and <u>subtract</u> - \$0  Extension Fee							<b>Sec.</b>	
7. Enter any previous extenses							148/248	
9. If Terminal Disclaimer attached, add Rule 20(d) Official fee					+ \$180	+ \$0	126 126	
10. If IDS attached requires Official Fee under Rule 37 (c),						+ \$0	146/246	
or if Rule 97(d) Request						+ \$0	149/249	
11. After-Final Request Fee per rules 129(a) and 17(f) x \$750/375 ea 12. No. of additional inventions for examination per Rule 129(b) + \$750/375							1179/127	
12. No. of additional inventions for examination per Nuic 125(5)								
14. Petition fee for TOTAL FEE =							\$0	
15.  16. *If the entry in this space is less than entry in next space, the "Present Extra" result is "0".  17. **If the "Highest number previously paid for" in this space is less than 20, write "20" in this space.  18. **If the "Highest number previously paid for" in this space is less than 3, write "3" in this space.							PLEASE CHARGE OUR DEP. ACCT	

18. \*\*\*If the "Highest number previously paid for" in this space is less than 3, write "3" in this space.

Our Deposit Account No. 03-3975) 276658 (Our Order No. 37003

CHARGE STATEMENT: The Commissioner is hereby authorized to charge any fee specifically authorized hereafter, or any missing or insufficient fee(s) filed, or asserted to be <u>CHARGE STATEMENT.</u> The Commissioner is necess, additionable to charge any necesspeciment, and which may be required under Rules 16-18 (missing or insufficiencies only) now or filed, or which should have been filed herewith or concerning any paper filed hereafter, and which may be required under Rules 16-18 (missing or insufficiencies only) now or hereafter relative to this application and the resulting Official Document under Rule 20, or credit any overpayment, to our Accounting/Order Nos. shown above, for which purpose a Query: Is appeal deadline now? If

This CHARGE STATEMENT does not authorize charge of the issue fee until/unless an issue fee transmittal sheet is filed.


so, file Notice of Appeals separately.

Pillsbury Winthrop LLP Intellectual Property Group Thomas A. Cawley, Jr., Ph.D. By Atty:

40944 Reg. No.

P.O. Box 10500 McLean, VA 22102 Tel: (703) 905-2000

(703) 905-2500 (703) 905-2144



## TED STATES PATENT AND TRADEMARK OFFICE

In re PATENT APPLICATION OF

Nabil HANNA et al.

Group Art Unit: 1644 Examiner: Phillip Gambel

Application Serial No. 09/772,938

Filed: January 31, 2001

Title: TREATMENT OF B CELL MALIGNANCIES USING COMBINATION OF B CELL

DEPLETING ANTIBODY AND IMMUNE MODULATING ANTIBODY RELATED

**APPLICATIONS** 

REQUEST FOR RECONSIDERATION

Mail Stop AF Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

This is in response to the official action [final rejection] dated April 8, 2003, wherein Sir: the claims were rejected under 35 U.S.C § 103(a) as well as the doctrine of obviousness-type double patenting.